<SEC-DOCUMENT>0001193125-12-041219.txt : 20120206
<SEC-HEADER>0001193125-12-041219.hdr.sgml : 20120206
<ACCEPTANCE-DATETIME>20120206163255
ACCESSION NUMBER:		0001193125-12-041219
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120202
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120206
DATE AS OF CHANGE:		20120206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IRIDEX CORP
		CENTRAL INDEX KEY:			0001006045
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				770210467
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1230

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27598
		FILM NUMBER:		12574024

	BUSINESS ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		6509404700

	MAIL ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d294543d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, DC 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of The </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported) February&nbsp;2, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>IRIDEX CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-27598</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>77-0210467</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction&nbsp;of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer<BR>Identification No.)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1212 Terra Bella Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Mountain View, California 94043 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices,
including zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(650) 940-4700 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name
or former address, if changed since last report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Completion of Acquisition or Disposition of Assets. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As previously disclosed, on December&nbsp;30, 2011, IRIDEX Corporation (&#147;IRIDEX&#148;) entered into an Asset Purchase Agreement with Cutera, Inc. (&#147;Cutera&#148;) and U.S. Bank, National
Association, as Escrow Agent (the &#147;Asset Purchase Agreement&#148;). The Asset Purchase Agreement provides for the sale of substantially all of the assets of IRIDEX&#146;s aesthetic business. Cutera agreed to pay approximately $5.1 million in
cash for the assets of IRIDEX&#146;s aesthetic business, subject to certain adjustments, and to assume certain liabilities of IRIDEX and its affiliates relating to the aesthetic business, as described in the Asset Purchase Agreement. Following the
closing, IRIDEX will retain and focus on its ophthalmology business. The foregoing description of the Asset Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Asset Purchase Agreement, which was
filed as Exhibit 2.1 to IRIDEX&#146;s Current Report on Form 8-K filed on January&nbsp;3, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;2, 2012, IRIDEX completed
the sale of substantially all of the assets of IRIDEX&#146;s aesthetic business for $5,100,000, subject to certain post-closing adjustments, of which Cutera deposited an amount in cash equal to $510,000 in an escrow account established as of the
closing of the transaction in satisfaction of its obligations with respect to certain indemnifiable losses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the
transaction IRIDEX and Cutera entered into a license agreement, which permits Cutera to utilize certain IRIDEX owned intellectual property following the transaction, and a transition services and supply agreement, pursuant to which IRIDEX will
continue to support certain aspects of the aesthetics business following the closing of the transaction while that business is transitioned to Cutera. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;3, 2012, IRIDEX issued a press release announcing the closing of the transaction. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated February 3, 2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IRIDEX CORPORATION</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ DOMINIK BECK</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dominik Beck</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and
Chief Executive Officer</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: February&nbsp;6, 2012 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated February 3, 2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d294543dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g294543g63w11.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IRIDEX and Cutera Close Acquisition of </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IRIDEX&#146; Aesthetic Business Unit </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MOUNTAIN VIEW, Calif., Feb. 3, 2012</B> &#151; IRIDEX Corporation (NASDAQ: IRIX) today announced that IRIDEX and Cutera, Inc. (NASDAQ: CUTR) have closed their previously announced purchase agreement
for Cutera to acquire IRIDEX&#146; aesthetic business for approximately $5.1 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dominik Beck,
Ph.D., president and chief executive officer of IRIDEX, said, &#147;The energies and resources of the entire organization can now be focused on the substantial and growing ophthalmology opportunity that is core to IRIDEX&#146; past and future
successes. We intend on using that focus and all of our resources to drive growth in our core markets, where we enjoy brand leadership, by acquiring and developing additional consumable devices for use in the surgical setting and accelerating the
adoption of MicroPulse</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> technology &#150; a new paradigm
in the treatment of retinal diseases.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The parties also entered into an agreement for IRIDEX to supply Cutera with
transitional product and service support for a time period not disclosed. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About IRIDEX Corporation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile
laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical,
clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a
combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit our website at <U>www.iridex.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This announcement contains forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Act of 1934, as amended, relating to the Company&#146;s plans to focus on new products and increase revenues. These
statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks
contained in IRIDEX&#146; Annual Report on Form 10-K for the fiscal year ended January&nbsp;1, 2011 and Quarterly Reports on Form 10-Q for the quarters ended April&nbsp;2, 2011,&nbsp;July&nbsp;2, 2011 and October&nbsp;1, 2011, each of which was
filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contacts: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Jim Mackaness </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer of IRIDEX Corporation </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">+1-650-940-4700 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">IRIDEX Investor Relations
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Matt Clawson of Allen&nbsp;&amp; Caron </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">+1-949-474-4300, <U> </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>matt@allencaron.com</U> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g294543g63w11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g294543g63w11.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`9`!J`P$1``(1`0,1`?_$`+P```$#!`,!````````
M``````D#"`H"!`8+``4'`0$!``$$`P$```````````````@!`@8'`P4)!!``
M``8!`04$!P0'!@,)`0```0(#!`4&!P@`$1(3"2$4%18Q@2(7&!D*06$S)*'!
MX6*R(R51D=%")CDRHGCP<;$T-76UMK<:$0`!`@4"`P4%!@4#!0`````!``(1
M`P0%!B$2,4$'46%Q(A.!D:$R%-%"4B,5"/"QP>%B\7(U@J(S0R3_V@`,`P$`
M`A$#$0`_`)^AU.`0#=OW_?N_4.Q$GS_W/^;]FQ%SG_N?\W[-B+Z"V\=W#^G]
MFQ%CEMNU6H4#+6N[V&!J%3@6*DE.VFT3,?`5Z%8I<7,=RTQ*+M8^.:EX?Q%E
M"$WB`;]^U0(J@CN@?E[?[(9&8^LAI(Q5#NIZ.<V2\UY!`RR-\[Q3<48FD2@`
MF(I`Y2SW;,5U6Z,U"!Q%<5U291,7M`PAM5P:QN]S@&=JY'2II_\``TO/NTY]
MO!,/>_4R:-FH329;%IY%]'2#AG'1BNKBE*KR[=,R7=WA)6%H\W5&Q'!%!W@$
MDJ4AB"'&8-QAJR67S@QKFB2?O$PA_P!)U7!-F>D[;M>[M@/[IZF$.M/I,S5S
M?"%9&0;-CK=[G,3V;'>HZ":M6P`"\B[98(MUXR`PCDE=Y3+.J^@0H!Q&$I=X
MA;+`F.<T.;IW\?`+F=LCY=T.]NW[433&V8,99AK*=QQ9>*OD"LJ.560R]3FF
M,RV;R+?_`,U&2!6JIEHN5:&`2K-71$7")@W'(4>S:V5NFAQ#2($\="8&$8<N
M[FK6^<1;`GN^U>@E7`P@`%^P1]/]GJ^W:K0XLW/&UT805Q8\#<X051EN$=W#
MO]?[-BM7"K<0[N'=Z_V;$7T%=Y^#A]>_[M_HW;$2NQ$DIP]F_=]OIW?=L1)>
MQ^[^C8BY['[OZ-B)I6K[5YC[1YC(+W;FKJT6*=E%8#'>-X1]$1UCO-B28JRS
MQNG(33UG"UBI5:#:K2ECL4FNA%5^(05=NC@4I$U+PQYX`JTO:"`2(N,!WK7Y
M:TNL#JCU\Y9D:UIMEX>W)4N8,*VH&=AE5M/.&7G"H4\9IKQ1:VKJ+G+'%%<&
M1)D:ULY.V3(I@YBF5<:G32VV!@737)NHM6ZALTIWT3#&;-VF#!Q.XZ:0U6*9
M;GF/810FKNKP:N!+&`C<[L@.''F?<4SBEZ!$\W9,K9LL6#*VKG4#DFQQ-9C'
M5[N,L]4LUHF77=HZ-8"_DEGJ4:!S[S&=/#(-&J9S\)"DX=I4R>B73KIICK\D
MS(MK*.6-7$C8Z81!C.?F+M`(:E1GG=:L[SN\LQ_#Y)IIDYQ+?+N>);-7N!,-
M`W4D0@$<\?IMXBMY-PY@JP!IKB+WE[&66,@(),<;V"PUZINL9'I":U8E;*XE
MHV7G2S*EX`HOFK5`6HM3B1)<IB[:SE=7^GDJCGUM#A]&^FIWM;MFD1<'1VNT
MEGCM,.,8:+9,SI_G,^IDTU9E%;*G3FN)$N,(L@7`><?+$1Y:A"&U6=)&MZ:,
MS3.+KA57^%LNU)"-L-<N^&KA,-XB5C)(SD:_;ZBZ732,M'F=M%"&**3)XV=-
MSHG,!R[]MAXST]Z4]9\<?>K/0S+56L=#R$;`Z&@(@W58)D&>]2>F=XET%YF,
MKZ5YYMU(TU!U(5[@?J)ZWNG)D:*O&6KO:LUXN.LPCG.I"HMF[C.E;A@X$VL=
ME9A(NTX?/M.1-^/%7$[MT`%,,3-Q+D"J!H?J=T-RC!1,N,ETRIMLH-+Y@;HP
M&.W?K`</@MW8'U6L&9.%)*$N3<@/-)B(CO!`&OLB>^"V!73XZB6*==%"83%9
MGJ^O:DZXTL`KUI=RK1<BUY5<L<K?<6O90$YE6&93"9V$W"R)$IVIS&]C(I<)
MVCIWI4.#VQ)!?SAR6S)XA/\`*\%D.$>"(V!TSAQ%,4P=H;_L'=V#N$?2`#ZM
MJ*Q4D]/J_6&Q%63\8/7_``CL176Q$BJ7B$H[]WI^S8B1Y?W_`*/V[$75S,O%
MUV+DYZ=D6<3!PD:^F9B6D%BMF,9$Q31=_*2+YPH()-V;%F@910YA`I2@(B(`
M&Q%K9>M+K=R+K:U+.M.U,L#ZK,,E5.,MF5)56030'$&CTRC&W8OPX`%,'@4_
MEF-189!OH"8BSQ]*0D.N<S:'%,^==-\*J,[RIMKIW/;;F@.J'G1LMC1%SNX=
MGM6)YKEE%B%C-[F#?63?RY4OFYY):`/$@D]@AVK`HG"K["V,:HQ88^NF-,8K
ML8UG6+G/4B?B*Z_0?@@DC9D;!+PS.#GY%P5R5YSCJJE>@`&(!D]V[T6H,@Z>
MXQBM78L*K*07"BHW1((W39@#HZC4\`%"*LM^:9+ES+OF%)4.HILT$0!VM9&(
M$.'./M4[W#/2ZT;8FF-/62\7T(M<O^%S>/1618J3>*SF1UYZE/H"86R.N_</
M268DJ2;._1-N*9BX(GW8Z27$F;SAO.;Y=>Q5V^\53YM!.G;BR)+6ECHMARXQ
M^'BILVK%<:M3J.OM5,V55ME$!T(&#AJ#XA9CEC?\Q?1YV^G`.K@0^[^HX/[/
ML#<'_AMT]%_P-?\`[J;^<Y=E5_\`/4/^VJ_E)679PT%:8M2.6:_F+.>.XW)4
MY5L>2>-X6#L:CE6I(14K-+3:TLM#M%6P/+`@Y<'3;.5C*"T(<QD0(H;CVOH<
MLR3'Z1\C'ZE\F5,<'N#7$1(^'VKZKE8+)?S+F7*G9.>`8$@&'#_4*$7J7TW-
M:[JGU+:=<+U&X9=IF.,@V"K)PD/7)[)#V.J2[=BNC`VL85E-JKI12CXT;QN@
M356*@!A#B*8=O0_!<]QV[]+9$S/*RG%;5`M?*F$1>T`!KH'D8F"A7F&'72W9
MO4MPZ1/$Z0&S!,E\#$N\L1S;#5#TT<9VNW3%UBT:M56T/X;!&5,A.5\7GGI"
M20AL`:F@,E7G$-9&RZB!HREY";I%JUU9JD2.I7WI'2H`^AFIDXB=:^G%!B-S
MD7W')@G8U<!N:YORL>?-Z<?`D@=Q4F>F.8SLDM/T=Y;Z>1TX`>T_,6C3?#Q@
M#WP[5L^,'95@,Y8FI&5JVFJSCKA$B\<Q#E9)P]KD\S=N8NTU2241,9+Q6IV5
MB[C70%]DKAJ<`[`#;1RV>O52>GU?K#8BK)^,'K_A'8BNMB)!8#;R[M^[</V[
MMB)'<?[_`._]NQ$.[JC79"JZ2+36WKM=A'Y?LM6Q-8WB`*F63QY-N'5AR\FF
M*(@=,[C#U6GT0,)BE**O$(]FQ%K8-*,C,9K=9\U86XG,NNI7+]TL?>00:++Q
M,$2946BX-L@=-5+P^/=N112;%3%$$FB)``2@`!/3]L^(2V875WJM#0^Z%\O>
M1_Z6C86N/X(AVG#4J'77S)*N5F%#:*)S7R:"2)A8=3ZKR7!P_P`MNR'9R4V_
M1EJ_QIJMPJEB=6LSK*T2M75I^7<!WK%.0\F:1\OE[L$1-R./+K6*M9VN)QL8
M&%VNR!0C:+<KF*9@KP`Y/$G/,+J<`R"=*9,D/EN>Y['27:-:Y[H`@0@>WB#S
M[%(W"\KI\ML4BI?*>UVP,>V8WBYH&H[1X_T11Z;FNBZ7\".JUDQ>[U1W@/&%
MGE4:WD4S1:TS>/\`'D6[?L6M1N"2SBO904AZXT;1Z;MLZ%^MR"K/4$5#*@&#
M4]%/JZME+2ESJBHF-'/F8$GP65UCY=')?637?DR93G;>7E$8)D.(]0F1M1-^
MT(:D9YG2*Q><CZ2]>=YKT&P-)2U7J2*5EQDG3(.PK]^1D)I]!1K%LG.*)':$
M5>$7!`J0`7=F-QL3\?F7RSS'%XD5=*!'L(?Y??$PX:K':"Y,O'Z;=`-IFTT\
M^!\L3W1@/&"=)I-Z@5;U-Z5Z)EM=`U:S%;&]AJ[_`!938]U?)YKD>KJJ1DLI
M5:]O:O)&G`\7;OF[M^JT;)LW"2;IT0P&,/399C53AV13\?KR162F^4<B(1_J
MNQQB_2\FL,B^6\%LB9HYH&@UA[^U-1OV8L8:$L/2\7DFOY9J<8W5F+7/XQPA
MCN].+[F.[SCI>7L%RU`:H(^"9T2#<6Z>>NEW_<9M!HR14,B$@[23(D/#9K37
M9;<)-"9C15,#6ATQVDMO)H)!@T=@X+LKK74.-T,ZYLEE\F&XAC1N+^9`CJ>&
MI\5">UY,G.I;&><[A(0T)$6.R/IG,,)%UAJT0@ZU+1ZJLG'P]?69I(E5:QE<
M;^'%>``+/Q3%<XF.H<P^@^1]-9--T-?C;C(J:R53">Q[0"&S&`#<T\G0<X1'
M(D*$^.9P^IZPRK\SU::AFO=)>Q^D6O()B.8!:#X@*8]].=J;E\_:2FZUAE"/
M9.7IV+<L"F5<QA\>LD=.8KRHX*EOY:`2V5<.2<RN4`[7<RH<1XU#"/FZY_IN
MAJ6[O@-#\8*<+]VUQX$NCX`G0>"D2D]/J_6&W(KU63\8/7_".Q%=;$2*IN$2
MANW^G[=B)'F?=^G]FQ$%SKIF9_!J^,Z4<(O"16I)2LG:J2)')+@GH?U2#`G0
M&/W;U]XK<L%?8$^[_-NV(H$^@%6LM=/.`G-GC59FG-9!!W>(B,=$8O9:KH9!
M>N;?%M'AQ(5M)O:Z@NF4W$0>,Q2\1>+B#T8Z9LFS.@<FCMK]E9^GU3HQX/<^
M<6F/(Z@]R@YG4BBE]<)E==6&93>M)(':&M8W;#LTX]_!;/'2[DG"N6<(4B[:
M=FQ&.&GD6BSHK-I3YNA,&</&H@Q29L*S.1$&NW:,P(*0*(H';+"3B355`.,?
M.ZOEU\BMGLN#C,GF8=^NXQT!,2?ETC"/:81*FK1FWLHY;Z,!M(&#:UK8$1$8
M0'C"/$\T,#K#X^L^8X.F8[R=GBC:6M#D=%/KGGO*EN782<YD&Z$EFT=0L14&
MEI/&-EGYE))):2630.";E11!,4W8E%N;+<)R"CL$]U<RC^NK@TM9$EK&`C5S
MG`&!'%NG+B(KHLEMSKS;W2#4NI:4N!<X"+S#7:&F$=W`Z^]"<IM,SUCQ[AC&
MVG.EY^D-/I<3:K*WBV+S9:<5437[DW&F7%ZI+YRR+IJQ%:$(Q).,J:)$'-<:
M6MF224*\7.4AMR9"=Q=;O17>JKZFNFB7<*^IES3L#G26>F#!CID(ZQU.WLAW
M=904-13RJ5M&QSK93T[Y<3M;..XZELN,#P_$(IUO28Q,PP'G9O\`!EG"5S?I
MMO\`XE5=46%,P5YGCK5/IIOD9`N5Z3=,@TJP@QF%4>_1A86159(MVRX.$E2H
M.2I@NG?G^4MR:5)F7:D$K(9$`:F6[U!.&GS1#=L(:<>*8E8#8JB<+54;K3-,
M1(<-GI'7Y81W<5)4M5AB:U69^?LHK$KL+#R$E-J(QDA-@2*9,U%GYBP\0RDY
M&3W-RCO01;+J*=O"F/8&VKFF9&8^80V7IM+22Z,=8Z"!X<"L_?*,O8T>:61Y
MM(Z=OM6O#UWW73SD;.NHVZZ<Z^-;P'/>.+P<>2%-4XM9ZC5Q97F8AZJ9)HYK
MD+-6-!RX09+(-E@$ZBAD$14$FWI1TFH+Y;^DSWY',$SU*1[F.W;_`,LM,`XG
M@1%H@(QUU4#.K%92S^J-/3V:7LFLG-$`(`^81.G-$V^D6&4/IL8"J1@+)/'-
MY3;++F5&Q%C$]1MT4A46A1`0-5.]FE3%$1`1><T"@/M;>;CC*$-T#\\?>/ZJ
M=\'NEC?\WIB/BIF!/2/_`'?K#:Q7JLGXP>O^$=B*ZV(D51+V;]V_M^S?L1);
MR?=_=^S8B']U,Z.PN.E&U2S]FN_CL8SM?R78V;=1P@HOCV,5=5K+G"HV514$
M4L0VN?.!?:`PE`!`0'=L1:[+IA0-/QAGLVDG4J9DC7]..K]C2LJMK`8K>)>X
MX4R&BR?2LP/'P)U!ZX9F4<*B86ZC%R`B(IG$1EQTLR.NK>B=^QZWO)OM*[?+
M#8[_`*<M87$<-`=\`#'3@HV=0K%2TG5VT7^K9&T3@&OC\I>TD"/?#;Q4^E_K
MCR-J#D'>,>F7BN&R=%Q!B5Z8U;9':RE2T@8[\..FQ<M*2=@BRL.>IV$0*9-)
MA6DTX=,Z9"K/RI[]\5I=-3T\R7/R%TS;,)<UK-9CQN.KB-`"X%I#B'1!.V!!
M.^G5OK32RT28RP=OJ:-8T@1V@$AQ@(&+06Z@1C$#N*UTWDF;F5S)DK-<_GG6
MHZ8+H5'4EF*GP-UJF%)!RIS!]R&GAPZ:XVQ]`(%.9+EM^*57*;B5>F.;;Z*F
M]/#/IK?*;(MD6AS&1#GM'$/<`"XD>*Y&4DE\PS:IWJUNT[=/*UT-'0.GE.O,
M]@!0_LC]&7+&2<]U3,64>H'E6P:E),;1.TO*\)1(FNM*,-23B%XF/KL7&V--
MU7XMF,FJ";2+<Q[4G,/S$G/.7%3/K9U-H[30BST%FHS97C\P3H3)CCVAY8XC
MWK"JKI]47.H=<;E=*L7@'\MTEQ9+:.0+`YH_[3[$0J0Z<#?)].@)C43F:?N>
MJZD\PE"UGX<JD%IXSC5F**3=.+C%I&E.'T?<XINJCS'+*:1=1SP3&`S0F_?M
M@1N\RG+VT;`RW.CNEO\`/[H@P]BS27;I-1+#ITR-4W[[=-=>,(1CSBL1)J+U
M?Z)@",UF4]34I@2-,4C;69I\ICL]QJ4:D(I>):D-/L0+Z3BTVJ("=W8:GWUB
M)=YE&3?<._D=26ZXO]6UGZ:<6B,IY^<P^ZZ$-?\`(A6?47"V21]5&>TN,7-'
M`'@".[N_HHAWU`.=]."&2\[Y=TSVFM6JMY6QM0TO':*J@XK<]EF_0SEI,/8=
M=GN3&56K`LW,D7ED5!Z57FE!;F;2?Q#(KIBW0"[3;I4.:^94-IJ>6[<2'O#R
M&MT/E+6.,1Y0!Q$0#H3(K%;+WUCMS+9*;,VRW5$]PA!K&%H.Z,-2YS?*-8GA
MQ4B?Z;C3G)X,TAJ$G&163B%K6,\4&1.T3;+HVBM1LUE;+B0."D$7(1F4\S/X
M9P(^T1Y"*I&]I/:(!8'N&[@#'[?BI)C=M<T_B,/#D5(Z)Z?5^L-N1559/Q@]
M?\([$5UL1(JE`=PCO^W8B2X`^_\`1_AL1=9+P\7.1\A#33!K+0\O'/HF5C'Z
M";EE(QDFV592#!VW4*9-=H\:+'34(8!*<IMP[PV(M;MUJ]">1=#.II[JAQ]6
M7=CK-8KC6JYEA637B'(^E=-Q%U+&>7BB5,Q9";QI$J1U%O"P[E6DE&0TNK_)
MG#J$S[IMG-7@N1MO(9ZM(_R5$J$091\NH\.'*,5B6:XU)S"P3;9/(E7"7YI+
M^!#AJTB&O'1P'$>`1*-'_7ISA2=.-,I]2J6*,VU>OP#:"QU>;$O.UZ=AX1@@
MFTBJU;X>N()QTK*5=%(K8YP+'+K`F'-$QMZAI*,_;UBW4$',,,NA_3ZQQFF2
MW4RYA^9@TT'.'`$]BC^>LEWPR1*L.4VX?J$AWIB:XZ.9'RNB#K'MX%2",!=4
MC3FYT:4+.N=M06-B7QK5D299KD0"$/=6V2B'6-,4RNXD;N7MG<O0?*<AD1)-
M8CI$I%N8*9S*%CC<>F^72,JG8];*"JG.;-#0]S';(=I="`TY\/:M^6[.L:F6
M1MXJZJFEL,HN+`X%\>X<5\P]G#*NI#!-1U*Q$BVI=HR96-3=ZPW7GH,G4=1J
MO4G<5&XZKUG5%NHDZ<S;2KI.;$H4RG"K(KIMCE(DF(8E>+346*]5%HJ1_P#=
M*(!:>1('NXKN[1<*.X6^3=:-^^FF@D>&OV+)=//5>TD9UP,3*UDRG2\+V2$K
M3=[DO'M\LD='62D38-/SR48P='34NL(L\`PQSJ-*Y!\D8@<)%A.D3N[ET]S6
MQW&5:)UOK9['%NR:UCB'`\R8+HK9G^-5]H?<*2JI)98#%CGM!B.4.)0*I+Z@
M+54QH$]%A2,'(3;=*;!CFJ186J)%M`(.7(1UGE,9NY!2!:R7@O*5625D"-$E
MS;E$1W&3VD/2_M@HI,BFO=]KILFW.:)E3NT]$<=ITTCJ.]:.NG[BKAZC[19*
M)DZO>_9+#=8NCQ&NO\!1O=+>'<C]4'633YFJP?FO$5"RA(O:$A.1YFL+G[4B
M\>'M,I.3#1HW:-?=ICU5ZK9[:HFF1HR@&Q&!2E=3#-$VK>K^;4%_KI6/8UY,
M3MH$N5#03G-&T37?B,`0"=?,>U;5Z<8C5V6D=?+[YLCKANF1XRVD[O3'9KQA
MIH.Q;/W`>&:_@/#]$Q+77+I^UI\29N_GGG_JEKL\B[=3%QN<T?><%IBYVR1>
M2;T?09PX-N[`#;3"V>O8">GU?K#8BK)^,'K_`(1V(KK8BMUQ$!+N$?0.Q$AO
M'^T?[QV(OF\?[=B)KVJW2?CC5QC8U"O0+Q$I&JO9&DW>-:1S^8I<T_CW4/(+
M)QLLW>0=EK=D@WJT?.P,FW<Q,Y&N%6SI(0X#DK$ZCD>/?X]J'S&+M2M?]KFZ
M-FJ?I_Y;L-ZTH5N*9TBRORR3W`,S+NEL-7]<S@K87>GW(UF>E1BYYWO*H2D6
M5\QM$<H(H1CBP-2I*AL+`.J&3]/+@Q]GF%U&7[W23':2=">Z(`X'V+#LNPBP
MYA2.DW:2/5#2&S0`7-]G/7771#_CM9F/ZY8E:?GVEWW3GE&-`J4W5\H4^9B5
M&JI!Y8\IRM&HR::0H&'AYZ"(&(;V3#O[9K8S^X_`[^&/OH%OO@(W:?ED?>BZ
M!&XCY3&,>"BMD703+:![OT&9]5;7`P\T'CL&T[=.V$1#BB68PZPKS%^FN8TY
MT?..'DZ/)$R$P@KJZM:877'=7RBW:AD&MU9FJ;NJR$TNU67:N%B$6BEWKGE`
MJ!DN7A&3X!TMR[.V9=)O=+3T;X.?)<YNYY;#4QU/`#V+)K1D'4_&,3.+RK7-
M=/;Y6NV1(!Y`CA&/(\T-BS:V=/-<79P]9EGV4[&!4VL%6,=0[ZPOW[A,H)-6
M;9[W9!HBL<`X=R7-/Z-P#Z-MEW_]PW3:R6_;1U`KZU@@T;>!&@AH(>Q8+C_1
M3J!>*F$^E%OHR8N)(.A_QBX_#Q7L.$=!NM_J17UC1+ECZ[X=QBLX:/#8*K(`
MUR_:HY0Z2[*2RU.R+<T'@NAASBBM*V@B+@Y1_I</*N!*0(=]2^M^4YXSZ-@-
M)9'D!TMKB"^'XS&+@?PF(4E\&Z3X]ACQ6U)9576.CW,;Y.Y@AH8_>T/@II%7
MI^D3H":1XW-.:8<'\^H%<Q&P0P_5EY%O7FDLHYEV>)L,1<X_9.H^IM5(]Q+S
MT[+.TY6TRB2LE*+'5%JV;:5F`"</2:[T=IU)CJ8=\(G7W+;)U$8_Z(RFGW.-
M$U+86QSGC%[J3=47)M=0L4%XS'+0TRR**Z[&0AYF*<"96/F(259KM'20F.4C
MA`X%.<NXPU5J]C)Z?5^L-B*LGXP>O^$=B*ZV(D52@.X1W_;L1)<`??\`H_PV
M(N<L/O\`^WJV(N<`??\`H_PV(NFL%9KUMAY"N6J#A[-7)=L+26K]ABV$U"RC
M83E/R)",DF[ED\0XB_\``H0Q=^X=V\`VI")B3I#A_&OQ50=IB.*&/FWH]:.L
MUQYHI6N2M4B``PH5$J%5R5C=F*CLSIP6'QQFJLY)K%30<BH8ATX%*)*)1[-V
M[;C,B2="V+?$\>1CQT/?#M!5KO4,X3VO<V:.R$(<Q"$-?!#VE/ICM#[^RQ,R
M%:PLG'-4")3;#X;()FO+.T4P(U>M_`\@0-9BO:(0RR1(E9-<_%O*4#<(<I`<
MWS[C,_%N<#[@8?!<C7N$X3C`PY0$#[()V.#>A-HSPRN5RDUF%@5.15Y#8YK.
M/-/<!(E(00.A*.\'5*G7R0:N3G,91NXL"B"G$)1()-Q=K'2I+_G8"[MUC_-<
M[:R=+89<D[&'D/[Q19\:XDQGARL-Z7BFBU;'M3:J*+I0-2A&$*P4=+`7GOWA
M&:"9Y&2<"7>JY<&575'M.<1[=J[6PVG5OB5\L&GYP"8Q6+YTT\X1U-T%QBW4
M!C&HY:QZZEHR>5JESBTY*+";A5A7BIAN`&279RD>H(BBNB<BA`,8`'<80$`\
M&)<2WLTA_**JX[G;N``X+.<=8\HV)J-6,;8SJD'1J#2XEM`U.H5I@C%P-?AV
M1>!M'QC!N4J3=NGVCN#M,8PF$1,(B-RHLO)Z?5^L-B*LGXP>O^$=B*ZV(@B=
M;C+'40TNZ:[_`*P-&&<\'4:DZ>\92=LRABW*N&5KY.7I9.?8(I2-2N:<\S1K
MSAG&NA3[FNS52<&`3"JF.[8B&_T1M7W62ZJNG>_ZG+7JETO8UH[*P9-P_3JG
M'Z9%)>QER3$4V%>URZ3#Y.Z1K`M9@IFS-5U(\I55)!)!1(RB0'`P$3"],'57
MZZVI3JG9=Z6;74=HZI]\P[-YGB9C*;K32]F:G+*8>>"V?N(^$;V>/E4RSPG*
M9(#J%%+MXA'=O$B=GU`>I7UR.C&VHV5]6D+HVUF:7KS<$Z*[ON)J?<<0W*LV
M20C9"6CX1_&N9I^SB9%XPAG;ABJ=M*,W(MU$E3IF$H[$0SK%U[NL*\U=:0]-
M>'=1NE7(M=UN06!+5B+)DMIE/5?`8K/%C<U4D/?:X:T/%VE@Q]98U\QE"-'#
MA!PHT%1!3A4`"D1G^L9J0ZR_3%T8535E6]5^F')84US3Z%FRO.-+_@1IRW7B
MW33",NU+67O$D$;"QK1U&QRD8H!U#"@9WS!$YTRD75]//*/7ZZAFC/%6L*FZ
MUM#>/8[+#*T.X:A6?29/RCV/-5[;.504I6?C+FF@!G[N".MQ(M3@DFH7L,;?
MN(O.KSUX-?O2ZU/4/`'6<TV8I7P_DURJ%(U<Z4E+2C5744@Z08O)HU6LKV3+
M+A!F7(M+1O,C91B@J"J:#D@I\9$U7JP]87JXZ#-9F"\+8MU):3\IX>U@158R
M7I\N+;3_`,P]?QQDK(;FI5!I9G8V1R2P+1C+E./$&A^%^@(*<I(YN`"(H6KN
M.^HSTT:<,P9\JFL+1)G"0Q!2YB_/L85[2-8Z]9[+`5MLI(SR=;=.KC--G4VT
MBT%5T&ITB@ZY0D*<#B4#$3:NJGU&^KWIWT1Z=>IEI(M6%9/31DK#N"I;*^-K
M=@EQ(Y'Q+=K_`%9HYG+;+/G\NW.I3I"W.RQIVPMT%8EP=,A^(A^(I$_KH<]1
M/*^NOIOW?5;J2U!X:D+]"67(C&X.:Q0D,=U[3PQJ4,BY:-+]'O)Q="?128@2
MPF?\;=LNQ<\@HB*1Q`B;KT-M8'5UZ@>1K_G7-V4,#R>@*AWR_P"/<=VF`P*Y
MH=QU.N(-Q,0\==*)SYUVXJE0C'*39TY7<<XRJYS,B%,=-<Z9%*4V(A`=?3_9
MRZAG_3U+_P#S</L1"T^C<_VFK1_U>99_^F8KV(H^VFC4-+Z7/JD]>N7H3`.<
M=2SR*R9K+C5,8:>:U&VS(Z[-_,?FIYM#RDO"ME(B%22$[HXK@8A3!P@8>S8B
M=1K@UT9S^J.E*[T\NGU@5;$V/,4W:*S7FZ\:C[Y4*G:&YH5O-U&*/Y&B'4M,
M)0-5DK&\*Z38&DWJKM1NFH1J02B8B9;J=TKPFB#Z@+HY:2Z_-KV9C@JL=/JF
MN;*X**9K%/'RO/SEIG4FY@`[-G+V>7>.$&X[Q014*GO'AW[$4ISZM3MZ+N9_
MW<O:?Q#UY,CP[?[]B+W3Z9?_`&3M%W_M64__`-FR!L1,P^L)H%8L/28:W65C
MB.K+CC4GBE_5)0Q$A7CCVAM8ZU.I`IR^,&LC&.@*H0H@!SI)B._AV(H3NIG(
MMYMF,>@-;)%F]N]KJN!U:O68,'!6+ZPQ^.-;N3H6D5A"1D#B@DNZ81S:/174
M$$4R@01W%*(;$4VK*/40ZB%\ZE?26Q#E?1CFCI^XLR/G/+[.XEF\Y8_R5`Y]
M0C\02SMM1IEOC0QV!&-;<(IR149`>(Z@E,D'L".Q%)<S'B#'V=\5Y$PEE&O-
M+1C?*51G:1<Z^Z0;G1DX&Q1JT<]1("B*B:+E$B_-;J`7B1<)D4*/$4!V(M1K
M2(IWI#U\:A^DO):S%*;H9SIJ=IF"]3F5<?N6LW%VC&=-OG?H!XM(H$(6%F")
M2`1$\LW,#9%87*;@%VR`D,1;<C"&)\;X)Q3CK#6'JW&U#%V-*G$4VB5N(X1C
MXNMPK0C:.(BH4QQ=JN4B\]5P8QE'2JIE3F,8XB)%ZUL1`/\`J,M3>GK%?2]U
MB87R+F?'--R]F#`4JUQ;C">M<1'WW("BMIA(SF5.JKN2S,XV0>F$BRJ")TT0
M*8QQ*!1$"(1_TD.LW25B3INWO$V4]2.%\<Y-A]0F9<FR=#N^0*]5[.SQVPQ_
M0)%]>%(N9>LUSU9BQ@WBJ[X@&;H$:JBH8G".Q$)/II:O]+M3^J0U7:CK3GO&
M%8P)D2^ZO&](R]8K9&0F/[,>WRX>5#1MFDEFT8HA9>2(L5#*%3=;R\LQA,4!
M(G"]=#2[ECHP=2?$76<T01AH[$V5<@FD\HUV+YS>I0V5)U-9W?Z-84X\010H
M&H*L&<.D.SEH2Q7?`!!*U`2)A>N#J.:6M6G7VZ=.NVE9`CH#"2".B*>R;)69
M1PP]S\M5[X[D+_6KJLX;HI-UZ*"X]\=)<;0Z(`N0XIFW[$4B_P"J6US:.<J]
M(^PX]Q?J8PMD>[Y>R!A:U8VK%%R%6K3,6ZIP&29$9BVP[*(D'2SNK1Z]4D&Z
MD@0!:E=MC(\?,[-B++^@'U0^G5IQZ/6E>@YUUI:=L77RDMLC1]LHMMR5`QEU
M@WLEE&ZSK!L[J:C@9\QW<._1<)F3;J$.FH`@(]H`1#!ZR.M[)'U!60L0].'I
M2XVR%E_"M;R0VO.6]1+BLS]6Q9+6&.;NH2,<O)6=81S>&Q_1F$HY>J.GXH.)
M-V=,C-L<4TQ5(A=]:EEI4TVZL>DUIAP;G*@Y.JVAG"V+<5YLME7G&4PRK&0J
M[J)L5JR6>V+1?.1BIP\HZ>R+MB81<LR*@14H'#<)%.'SEUBNAY*,(O,UGU;Z
M2\JY`TZL[CDO#::-DC+'>(.Y^4Y&.<DQRD1NL_1LUICA\-`K?>=<JP$]&\=B
M(+>K[ZC:YW'IVZ9\=TBXX0PWU#.H+'%B9CP>[C%T#1KA^^V1W$P>3,A6>T/#
MGJ-IGZ,]9O8]1V<!01<*2!2`1%`%2+P[K;=#C2-IBZ+6$;]C*\X_A\RZ7>YS
M\WF*Q3,9#2.L!]F`6<AD-D2:>..=8[/)R12R]49@JLHG',U6R(&%43;$1'_I
ME>M#CG5MIFQWHZS_`)7@8_6!A-)/'5+C;;.-V-FSYC&&AGS^HSM52>K]XLUH
MIU7B%6,TW2%1T1%B1ZH!BK&,4BEG;$3']5/RVO--2^-SX'_.W@;WR)\5/N&\
MT^6^_&\1\I>]O^K>!^);^=W/\OS]_%[6Q%X'4/D<=_E?(/RH_%/*=J\<\H?"
M%W_R+X,Z\[>*^"_F/*?E[G^*\[\GW+CY_P#*XMB+&4?D#\:7=_D^\SG-^1R?
M@NX^\<:?=>5P>USN9P<O=[6_=N[=VQ$0S/\`\,ONID?BF]Q/N/[Q!>+>_P#]
MW_NI[WWQ+RSXC[Q?](]X\0Y?<.;[7.X>5[6[8B'@'R`NS=\GK_@/P[O@L_#X
M!YF[=_DY>_B^SA]/9L1958/D<^&4CS5\J3P;RFI[N/,'PA^&>1?,4]S?)'B7
MY7RGYM\4XNX?D_$>];_YW-V(K2I_(K\PQ_D;Y3/FO^9X5Y3^#WS#NY9N;X?X
M/_4OP=_%R_\`+OW]FQ$27&?NI\K,_<W[O?)/"3P_W9^7/*W!RR\ON?E;^D\/
M*W;N#LX=V[LV(ANW/Y%_G"U^\+Y3GG_S),^>/.?P?^</-W?E_,/FOQS^M>9/
M$^;WWOGYKG\7-]O?L18R'_\`/]O#A^3MOWANW?!5OW[^S=N^W?L19==/D=>(
MM_>)\J3Q;RY6>Z^=/A#\1\H^!-/)O=_'/S/ESRSR/#.'\KW'E\C^5P[$3O<^
M?!C[GZ_\47PP^X'OU:\J^_SW5>Y_Q+PY;R?Y?]X?^B^_>$<SPWNW\SNW%R/8
MW[$3<,&_)U]ZM/\`AJ^6E[[^]2GD#W&_"Y[U>_>"R7C/D_R#_J[O7EWOG>NY
/>WW+G<S^5Q[$1+=B+__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
